At the time of writing this document the entire planet is facing the pandemic caused by the SARS-CoV-2 virus. Contrary to the initial thoughts that most infected patients had symptoms, according to data from China collected in April 2020, at the time of the diagnosis, up to 80% of those confirmed to have the disease are asymptomatic, becoming an important source of contagion.1, 2, 3 Pan et al. reported that health workers in Wuhan (China) had a significantly higher risk of becoming infected (daily confirmed case rate in local health care workers was 130.5 per million while in the general population it was 41.5 per million).4 In this light, the scientific community is discussing the use of chemoprophylaxis in people at higher risk of infection using several alternatives including antimalarials (chloroquine or hydroxychloroquine) and antiretrovirals (lopinavir-ritonavir). At the time of writing this document the entire planet is facing the pandemic caused by the SARS-CoV-2 virus. Contrary to the initial thoughts that most infected patients had symptoms, according to data from China collected in April 2020, at the time of the diagnosis, up to 80% of those confirmed to have the disease are asymptomatic, becoming an important source of contagion.1, 2, 3 Pan et al. reported that health workers in Wuhan (China) had a significantly higher risk of becoming infected (daily confirmed case rate in local health care workers was 130.5 per million while in the general population it was 41.5 per million).4 In this light, the scientific community is discussing the use of chemoprophylaxis in people at higher risk of infection using several alternatives including antimalarials (chloroquine or hydroxychloroquine) and antiretrovirals (lopinavir-ritonavir).
Hydroxychloroquine as prophylaxis for coronavirus SARS-CoV-2 infection. review of the ongoing clinical trials / Galvis, V.; Spinelli, F. R.; Tello, A.; Sossa, C. L.; Higuera, J. D.; Gomez, E. D.; Serrano, S. E.; Camacho, P. A.; Velez, F. G.. - In: ARCHIVOS DE BRONCONEUMOLOGÍA. - ISSN 0300-2896. - 56:9(2020), pp. 606-608. [10.1016/j.arbres.2020.05.008]
Hydroxychloroquine as prophylaxis for coronavirus SARS-CoV-2 infection. review of the ongoing clinical trials
Spinelli F. R.;
2020
Abstract
At the time of writing this document the entire planet is facing the pandemic caused by the SARS-CoV-2 virus. Contrary to the initial thoughts that most infected patients had symptoms, according to data from China collected in April 2020, at the time of the diagnosis, up to 80% of those confirmed to have the disease are asymptomatic, becoming an important source of contagion.1, 2, 3 Pan et al. reported that health workers in Wuhan (China) had a significantly higher risk of becoming infected (daily confirmed case rate in local health care workers was 130.5 per million while in the general population it was 41.5 per million).4 In this light, the scientific community is discussing the use of chemoprophylaxis in people at higher risk of infection using several alternatives including antimalarials (chloroquine or hydroxychloroquine) and antiretrovirals (lopinavir-ritonavir). At the time of writing this document the entire planet is facing the pandemic caused by the SARS-CoV-2 virus. Contrary to the initial thoughts that most infected patients had symptoms, according to data from China collected in April 2020, at the time of the diagnosis, up to 80% of those confirmed to have the disease are asymptomatic, becoming an important source of contagion.1, 2, 3 Pan et al. reported that health workers in Wuhan (China) had a significantly higher risk of becoming infected (daily confirmed case rate in local health care workers was 130.5 per million while in the general population it was 41.5 per million).4 In this light, the scientific community is discussing the use of chemoprophylaxis in people at higher risk of infection using several alternatives including antimalarials (chloroquine or hydroxychloroquine) and antiretrovirals (lopinavir-ritonavir).File | Dimensione | Formato | |
---|---|---|---|
Galvis_Hydroxychloroquine_2020.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
128.61 kB
Formato
Adobe PDF
|
128.61 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.